Matthew Herper

A doctor inspired by his own fight against a rare malignancy to scour thousands of existing drugs to see if they can cure other diseases has a powerful new ally: Janet Woodcock, who for decades was one of the most influential figures at the Food and Drug Administration

More than once 23andMe's Anne Wojcicki has saved the company from corporate disaster. Can she do it again?

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

Two former Verily executives say that they are starting a new initiative, Highlander Health, to push forward an effort decades in the making.

Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech.

Kathy Giusti was diagnosed with multiple myeloma in 1996 and told she had three years to live. Twenty-eight years later, Giusti, 65, is thriving.

With new vaccine data released Tuesday, Vaxcyte, a San Carlos, Calif.-based firm, emerged as one of biotechnology’s hottest David-vs.-Goliath stories as

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a phase 3 study.

A combined vaccine candidate against influenza and Covid from Pfizer and BioNTech saw a setback, according to new data.

Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?

A special committee of the board of directors of 23andMe rejected an offer from the company’s CEO, Anne Wojcicki, to take the company private.

A trust controlled by 23andMe co-founder Anne Wojcicki has formally filed to take the genetic testing firm private.

The FDA approved a blood test intended to detect colon cancer, which many experts hope will help catch cases of the disease early enough so that they can be more easily treated.

Dolsten helped Pfizer outrace Moderna in the bid to develop a Covid vaccine but struggled to deliver on the expectations of its investors.

Marks’ unilateral decision to overrule three different review teams and approve the Duchenne therapy looks even more surprising on a close examination.

After a decade of drama, Grail starts public trading with high hopes for its multi-cancer test but also many issues yet to settle.

The story of its drug says a lot about why medicines are so tough to develop and why heart disease remains the biggest killer in the U.S.

The questions asked by reviewers, included in briefing documents posted Thursday, reveal why the agency decided to hold an advisory panel for the medicine.

Delfi is focusing on a single disease — lung cancer — where the utility of screening with existing technology is not in dispute.